Key information

Recruitment dates:

1 September, 2018 to 1 June, 2022
(Trial recruitment open)

Trial phase:

phase III

Treatment stage:


Trial investigator:

Dr. Ros Glasspool

Beatson West of Scotland Cancer Centre


PARP inhibitor retreatment



Clinical trial locations

Location list

Contact: Dr. Ros Glasspool
Beatson Cancer Centre, Glasgow
Contact: Dr. Rosemary Lord
Clatterbridge Cancer Centre, The Wirral
Contact: Dr. Johnathon Krell
Imperial College Hospital London
Contact: Dr. Emma Cattell
Musgrove Park Hospital, Taunton
Contact: Dr. Michelle Ferguson
Ninewells Hospital, Tayside


Olaparib is a PARP inhibitor, a new class of drugs targeting tumours with deficiencies in DNA repair mechanisms. PARP inhibitors have been found to prolong the time before ovarian cancer starts to grow again when given as maintenance treatment (treatment given to help keep cancer from coming back following initial treatment) after platinum based chemotherapy for patients who have relapsed. 

About the trial

The main purpose of this study is to see if Olaparib (study drug) re-treatment is effective in participants with ovarian cancer, who have already been treated with Olaparib or similar drugs. 

Olaparib is an oral treatment that is taken at home every day. A tablet formulation of olaparib is being tested in this study. It is a new formulation which is more convenient for participants than the approved capsule formulation because fewer tablets of olaparib need to be taken daily than with capsules.

Who can take part?

This trial is for women with relapsed non-mucinous epithelial ovarian cancer (EOC) (including primary peritoneal and/or fallopian tube cancer) (Non-mucinous EOC includes patients with serous, endometrioid, and transitional cell tumours, and those where one of these subtypes is predominant (>50%).

Also, that the BRCA 1or 2 gene mutation status is known.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.